Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Peter Ellis, MD, MPH and Lydia S. Dugdale, MD, MAR
Presenting all, including expensive, options to all patients means advocating not only for individual patients, but also for a just health care system.
AMA J Ethics. 2019;21(1):E26-31. doi:
10.1001/amajethics.2019.26.
Madeleine (Maddy) Kane, Rachel Bervell, MD, MS, Angela Y. Zhang, MD, and Jennifer Tsai, MD, MEd
Algorithms use race as an epidemiological shorthand, but clinically influential historical, social, and cultural determinants of health are still sources of variability.
AMA J Ethics. 2022;24(8):E720-728. doi:
10.1001/amajethics.2022.720.